Press release

September 2018

Scilex Announces Pricing and Availability of ZTlido™ for the Commercial Launch of its First Product in October of 2018

September 20, 2018

SAN DIEGO, September 19, 2018 – Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), today announced that the Wholesale Acquisition Cost (WAC) for ZTlido™ (lidocaine topical system) 1.8% (ZTLIDO) is $8.98 per patch and is now listed in pricing compendia. Scilex expects commercial availability of ZTlido through wholesale distribution in … Continue reading Scilex Announces Pricing and Availability of ZTlido™ for the Commercial Launch of its First Product in October of 2018

Scilex Presents ZTlido™ Data on Superior Adhesion over Lidocaine Patch Formulation

September 7, 2018

Data Presented at PAINWeek® Also Showed ZTlido Was Well-Tolerated and Demonstrated Bioequivalence to Lidoderm® Patch1,2 Study Results Make Strong Case for ZTlido as Non-Opioid Treatment for Post-Shingles Pain SAN DIEGO, September 7, 2018 – Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), today announced data showing ZTlido™ (lidocaine topical system) … Continue reading Scilex Presents ZTlido™ Data on Superior Adhesion over Lidocaine Patch Formulation
X

Share This Page

XS SM MD LG XL